

Fertility Sparing and Less Radical Surgery



Prof. Seung Cheol Kim, MD, PhD

Ewha Womans university Cancer Center for Women

Significance of tailoring the radicality of surgery

Five Classes of Extended Hysterectomy for Women With Cervical Cancer

M. STEVEN PIVER, MD, FACOG, FELIX RUTLEDGE, MD, FACOG
and JULIAN P. SMITH, MD, FACOG



Piver et al., Obstet Gynecol 1974

Indications of type II radical hysterectomy

- EORTC-GCG
 - In general, type II (modified) radical hysterectomy is indicated for the treatment of
 - **stage IA1 with extensive lymphovascular space invasion**
 - **stage IA2**
 - small stage IB1 (<1 cm stromal invasion) cervical cancers

Morbidity of radical hysterectomy comes from ..

- **Hysterectomy *per se*** **Conization**
– Infertility **Radical trachelectomy**
- **Lymphadenectomy** **Sentinel LN**
– Lymphocele/lymphedema, n/vessel injury
- **Parametrectomy** **Non radical surgery**
– Damage to autonomic nerve fibers a/w bladder, rectal & sexual dysfunction

Low incidence of parametrial involvement in small volume tumor (1)

TABLE 2. Literature review of treatment, frequency of positive nodes, parametrial involvement, and outcome of patients with stage IA2 according to the 1994 FIGO staging system

Authors	n	Treatment		Pos Nodes, n (%)	Pos. Param	Rec (+ node)	Fup, mo
		Cone/SH/RH	Node Diss, n				
Orlandi et al ⁶	16	NA	NA	1 (NA)	NA	2 (1)	83
Buckley et al ²	94	0/0/94	94	7 (7.4)	NA	5 (0)	5–282
Creasman et al ⁴	51	0/0/51	51	0	NA	0	≥60
Takeshima et al ⁷	33	0/4/29	29	1 (3.4)	0/29	1 (0)	≥48
Elliott et al ⁸	89	NA	59	2 (3.4)	NA	4 (NA)	60–300
Kodama et al ⁹	27	0/0/27	27	0	0/27	0	12–204
Smith et al ¹⁰	286	29/116/134*	127	1 (0.8)	NA	NA	1–119
Gadducci et al ⁵	23	0/NA/NA	23	0	NA	3 (0)	NA
Hirai et al ¹¹	6	0/0/6	6	0	0/6	1(0)	≥36
Plante et al ¹²	10	NA	10	0	NA	NA	NA
Schlaerth et al ¹³	8	8†/0/0	8	0	NA	0	≥24
Juretzka et al ¹⁴	6	0/0/6	6	0	NA	0	39
Ueda et al ¹⁵	37	0/0/37	37	1 (2.7)	NA	0	72–240
Siu et al ¹⁶	9	NA	9	0	NA	NA	NA
Lee et al ¹⁷	28	0/0/27	27	1 (3.7)	NA	1 (1)	36
Quinn et al ¹	238	NA	238	23 (9.7)	NA	NA	NA
Yamaguchi et al ¹⁸	46	0/0/46	46	2 (4.3)	NA	0	NA
Bisseling et al ¹⁹	9	2/3/4	7	0	0/4	0	72
Wright et al ²⁰	33	0/0/33	NA	NA	0/33	NA	NA
This study	14	0/10/4	4	0	0/4	0	9–119
Total	1063	39/123/498	805	39	0/103	17 (2)	

Low incidence of parametrial involvement in small volume tumor (2)

- Literature review of patients with low-risk pathological characteristics (including Tumor <2cm, stromal invasion <10mm, pelvic nodes(-), no LVSI)
- Risk of PI: **0.63%** (5/799)

Authors	No. of patients	Stage	Tumor size	LVSI	Depth of invasion	PI+ PLN-
Kinney 1995	83	IB	< 2cm	absent	0.4-1.8 cm	0/83
Covens 2002	842	IA-IB1	≤ 2cm vs. > 2cm	+/-	<10 mm vs. >10 mm	3/536
Sonoda 2004	89	IA-IB1	< 2cm			0/77
Stegeman 2007	103	IA-IB1	< 2cm	+/-	< 10mm	2/103

Low incidence of parametrial involvement in small volume tumor (3)

- Retrospective review of 594 pts, IA1~IIA, PI was found in 0.4% if
 - › Tumor < 2 cm
 - › No LVSI
 - › Node negative
- Retrospective review of 350 pts, IA2~IB1, No PI if
 - › Tumor < 2 cm
 - › No LVSI
 - › All grade

Parametrectomy is still needed in low risk early cervical cancer ?

- Hard to justify the morbidity of a radical hysterectomy and parametrectomy in low risk patients
 - Risk of PI < 1%
- Lymphadenectomy probably still justified although LN mets low < 5%
 - Could possibly be omitted in IA2/LVSI (-)

Low risk in early stage cervical cancer, NCI-C & CVM 1001

Candidate for simple hysterectomy + pelvic LND

NCI-C

1. Stage Ia2 ~ 1b1 (tumor < 2cm)
2. Depth of invasion: less than 50%

CVM 1001

1. Stage Ia1: must be LVSI+
2. Stage Ia2 ~ 1b1 (tumor < 2cm)
3. Depth of invasion <10 mm
4. No metastases on MR or CT of pelvis, & CXR

Needs of further considerations for fertility preservation in early cervical cancer

- Nearly 15% of all cervical cancers are diagnosed in women under the age of 40 years.
- Recently, the number of women wishing to have their first child when they are 35–39 years of age has increased.
- Cervical cancer cases diagnosed during childbearing years, in women who have not yet conceived, are therefore rising in number.

Fertility sparing surgery of Early cervical cancer

- Radical vaginal trachelectomy (RVT)
- Radical abdominal trachelectomy (RAT)
(laparoscopic, Robotic)
- Simple trachelectomy
- Conization with or without NACT

Indication of RVT

1. A desire for future fertility
2. Proven diagnosis of invasive cervical cancer
3. Squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, with exclusion of unfavorable histology (e.g., neuroendocrine carcinoma)
4. Stage IA1 with lymphovascular space invasion, stage IA2, or stage IB1
5. Tumor size ≤ 2 cm
6. Tumor limited to the cervix
7. No evidence of pelvic lymph node metastasis and/or other distant metastasis

Roy M, Plante M. Pregnancies after radical vaginal trachelectomy for early stage cervical cancer. *Am J Obstet Gynecol* 1998;179:1491-6.

Decisions also depend on the **presence of high-risk features for recurrence**

- ❖ exophytic tumor (≥ 2 cm), minimal stromal invasion
 - reasonable candidate for RVT
- ❖ LVSI (+) only – no contraindication
 - 30% of LVSI (+) in preop. assess \rightarrow only 5% had positive LN in intraop.

Beiner ME, Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. *Nat Clin Pract Oncol* 2007;4:353-61.

- ❖ preop. MRI – best imaging modality to help determine tumor diameter and volume, degree of endocervical extension, and parametrial involvement.

Peppercorn PD, Jeyarajah AR, Woolas R, Shepherd JH, Oram DH, Jacobs IJ, et al. Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-sparing surgery: initial experience. *Radiology* 1999;212:395-9.

Operative outcomes of RVT

Summary of operative outcomes of radical vaginal trachelectomy versus radical hysterectomy.

Author, year [reference]	N	Median operative time (min)		Median blood loss (ml)		Intraoperative complications (%)		Length of hospital stay (days)	
Alexandre-Sefre et al., 2006 [9]	29 RVT	260	$p = 0.0001$	400	$p = 0.0001$	12%	$p = 0.61$	6	$p = 0.0001$
	50 RH	187		1000		10%		11	
Beiner et al., 2008 [10]	90 RVT	174	$p = 0.75$	300	$p < 0.001$	13%	$p < 0.001$	1	$p < 0.001$
	90 RH	168		600		2%		6	
Marchiole et al., 2007 [11]	118 RVT	179	$p = \text{NS}$	12.7%	$p = \text{NS}$	2.5%	$p = \text{NS}$	NR	
	139 RVH			17.3%*		5.8%		NR	

N = number of patients;

RVT = radical vaginal trachelectomy; RH = radical hysterectomy;

NS = not significant; NR = not reported.

* Percent with blood transfusion.

- Longer operative times with RVT because of the slow learning curve
- Beiner ME et al. (Nat Clin Pract Oncol 2007;4:353–61)
 - Intraoperative complication rate of 4% (bladder inj., vascular inj.)
 - Postoperative complication rate of 12% (bladder hypotonia etc)

Oncologic outcomes of RVT

Summary of oncologic outcomes of radical vaginal trachelectomy vs. radical hysterectomy.

Author, year [reference]	N	Follow-up (months)	Recurrences		5-year RFS		5-year OS	
Marchiolo et al., 2007 [11]	118 RVT	95	7 (5.9%)	<i>p</i> = NS	95.5%	<i>p</i> = NS	95%	<i>p</i> = NS
	139 RVH	113	9 (3.5%)		94.7%		95%	
Beiner et al., 2008 [10]	90 RVT	51	5 (5.5%)	<i>p</i> = 0.17	95%	<i>p</i> = 0.55	99%	<i>p</i> = 0.55
	90 RVH	58	1 (1.1%)		100%		100%	

N = number of patients
 RVT = radical vaginal trachelectomy
 RVH = radical hysterectomy
 RFS = recurrence-free survival
 NS = not significant

no statistically significant difference in recurrences, 5-year recurrence-free survival, and overall survival rates

Summary of sites of tumor recurrence for radical vaginal trachelectomy (modified from Beiner and Covens [5]).

Reference	Central	Parametrium	Pelvic sidewall	Pelvic nodes	Para-aortic nodes	Supraclavicular nodes	Intra-abdominal	Distant metastases	Not reported	Total
Shepherd et al. [54]	1	1	2	-	-	-	-	-	1	5
Hertel et al. [14]	3	-	-	-	-	-	-	-	-	4
Mathevet et al. [13]/ Marchiolo et al. (2007) [11]	-	-	-	-	-	-	-	2	-	7
Covens et al. [57]	-	-	-	-	-	-	-	-	-	7
Plante et al. [19]	-	1	-	-	1	-	1 ^a	1 ^b	2	6
Sonoda et al. [12]	1	-	-	-	-	-	-	-	-	1
Burnett et al. [58]	-	-	-	-	-	-	-	-	-	2 ^c
Schlaerth et al. [20]	-	-	-	-	-	-	-	-	-	0
Combined data (%)	5 (16)	5 (16)	5 (16)	1 (3)	6 (19)	1 (3)	2 (6)	3 (10)	3 (10)	31

^a Mesocolon.

^b Neuroendocrine tumor.

^c Site of recurrence not reported.



ELSEVIER

Radical vaginal trachelectomy vs. radical hysterectomy for small early stage cervical cancer: A matched case–control study

M.E. Beiner ^a, J. Hauspy ^a, B. Rosen ^b, J. Murphy ^b, S. Laframboise ^b, S. Nofech-Mozes ^c,
N. Ismiil ^c, G. Rasty ^c, M.A. Khalifa ^c, A. Covens ^{a,*}

^a Division of Gynecologic Oncology, Toronto Sunnybrook Regional Cancer Center, University of Toronto, Toronto, Ontario, Canada

^b Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

^c Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Received 6 February 2008

Available online 9 June 2008

Surgical morbidity

	Radical vaginal trachelectomy, N=90	Radical hysterectomy, N=90	<i>p</i> value
Median OR time (hours) (range)	2.9 (1.5–5)	2.8 (1.6–5)	<i>p</i> =0.75
Median blood loss (ml) (range)	300 (100–1100)	600 (100–2300)	<i>p</i> <0.001
Transfusion (cases) (%)	2 (2%)	21 (23%)	<i>p</i> <0.0001
<u>Intra-operative</u> complications (%)	<u>12 (13%)</u>	<u>2 (2%)</u>	<i>p</i> <0.01
Infectious postoperative complications (%)	3 (3%)	10 (11%)	<i>p</i> = 0.08
Noninfectious postoperative complications (%)	1 (1%)	6 (7%)	<i>p</i> =0.12
Median time to normal urine residual (days) (range)	1 (1–49)	6 (2–63)	<i>p</i> <0.001
Median postoperative hospital stay (days) (range)	1 (0–7)	6 (1–20)	<i>p</i> <0.001

Recurrence rate : 5%

Term delivery rate : ≥50%

Procedure of choice for fertility sparing
surgery in early cervical cancer



Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: Prospective multicenter study of 100 patients with early cervical cancer

Hermann Hertel ^a, Christhardt Köhler ^b, Dorothee Grund ^b, Peter Hillemanns ^a, Marc Possover ^c, Wolfgang Michels ^d, Achim Schneider ^{b,*}
for the German Association of Gynecologic Oncologists (AGO)

^a Department of Gynecology, Medical School Hanover, Germany

^b Department of Gynecology, Charité Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany


^c Department of Gynecology, St. Elisabeth Hospital Hohenlind, Cologne, Germany

^d Department of Gynecology, Friedrich-Schiller-University Jena, Germany


Received 11 January 2006

Available online 11 May 2006

recurrence free survival



survival



Ds free survival : 97%
Overall SR : 98%

RVT is an oncologically appropriate approach

Risk factors for recurrence

- **Tumor size**

> 2cm → 29% recur
≤ 2cm → 1.6% recur

Marchiole P, Benchaib M, Buenerd A, Lazlo E, Dargent D, Mathevet P. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). *Gynecol Oncol* 2007;106:132-41.

2.5-3cm size, exophytic type, small stromal invasion → RVT candidate

- **LVSI**

LVSI (+) in 28% RVT → 12% recur

LVSI (-) in 72% RVT → 2% recur

If, LVSI (+) → increased recurrence rate

Plante M, Renaud MC, Francois H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. *Gynecol Oncol* 2004;94:614-23.

Mathevet P, Laszlo de Kaszon E, Dargent D. Fertility preservation in early cervical cancer. *Gynecol Obstet Fertil* 2003;31:706-12.

But, LVSI (+) alone is not absolute contraindication for RVT.

Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? *Gynecol Oncol* 2004;92:525-9.

Risk factors for Recurrence

- Unfavorable histology
 - **Adenocarcinoma, adenosquamous type vs squamous type**
 - very early stage cancers, the difference in recurrence and overall survival rates between these histologies appears to be negligible

Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010;116:140-6.

Multivariate analysis that histology was not an independent negative prognostic factor for recurrence.

Marchiole P, Benchaib M, Buenerd A, Lazlo E, Dargent D, Mathevet P. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007;106:132-41.

Fertility sparing surgery of Early cervical cancer

- Radical vaginal trachelectomy (RVT)
- Radical abdominal trachelectomy (RAT)
(laparoscopic, Robotic)
- Simple trachelectomy
- Conization with or without NACT

Indication of RAT

1. Cervical cancer in patients with distorted vaginal anatomy
2. Cervical carcinoma in pediatric patients
3. Cancer in cervical stump after subtotal hysterectomy
4. Bulky exophytic cervical cancer
5. Extent and location of cervical cancer that requires increased radially of parametrial resection

- Most gynecologic oncologists are not trained in radical vaginal surgery. RAT is a feasible alternative to RVT.
- Pediatric patients are not candidates for the vaginal approach

Abu-Rustum NR, Su W, Levine DA, Boyd J, Sonoda Y, Laquaglia MP. Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach. *Gynecol Oncol* 2005;97:296-300.

Operative outcomes of RAT

Summary of two largest series on radical abdominal trachelectomy.

Author, year [reference]	N	Stage			Operative time (min)	Hospital stay in days (range)	Adjuvant treatment	Median follow-up in months (range)	Recurrences
		IA2	IB1	IB2					
Ungar et al., 2005 [44]	33	10	15	5	226	14 (12-22)	3 (9%)	47 (14-75)	0
Abu-Rustum et al., 2008 [40]	22	0	22	0	298	4 (3-6)	7 (32%)	12 (1-35)	0

Among 33 patients - ureteral injury (1)

Ungar L, Palfalvi L, Hogg R, Siklos P, Smith R, Del Priore G, et al. Abdominal radical trachelectomy: a fertility-preserving option for women with early cervical cancer. *Br J Obstet Gynecol* 2005;112:366-9.

Among 22 patients - infected lymphocele(2), cerclage erosion(1), lymphedema(1)

Abu-Rustum NR, Su W, Levine DA, Boyd J, Sonoda Y, Laquaglia MP. Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach. *Gynecol Oncol* 2005;97:296-300.

RVT(28) vs RAT(15)

- In RAT, more bleeding, shorter time of surgery

Einstein MH, Park KJ, Sonoda Y, Carter J, Chi DS, Barakat RR, et al. Radical vaginal versus abdominal trachelectomy for stage Ib1 cervical cancer: a comparison of surgical and pathologic outcomes. *Gynecol Oncol* 2009;112:73-7.



Abdominal radical trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer in a series of 61 women

Hiroshi Nishio ^a, Takuma Fujii ^{a,*}, Kaori Kameyama ^b, Nobuyuki Susumu ^a, Masaru Nakamura ^a, Takashi Iwata ^a, Daisuke Aoki ^a

^a Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

^b Department of Pathology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Surgical outcomes.

Surgical outcomes	No. of patients (%)
Number of lymph nodes retrieved	
Median (range)	38 (17–69)
Positive lymph nodes	7 (11.4%)
Transfusion	
Autotransfusion	60 (98.4%)
Allotransfusion	8 (13.1%)
Residual disease in specimen ^a	28 (45.9%)
Median estimated blood loss (ml)	1160 (352–5568)
2002/03–2006/02 (30 cases)	2010 (704–5568)
2006/03–2008/03 (31 cases)	1032 (352–2195)
Median length of stay (days) ^b	23 (11–63)
Median operative time (min) ^c	436 (317–586)
Median time to recovery of bladder dysfunction (days) ^d	15 (7–35)

Pregnancy outcomes.

Fertility treatment	Time to pregnancy (months)	Intraoperative cerclage	Cerclage during pregnancy	Termination (gestational week)
AIH	14	–	+	24
IVF-ET	45	+	–	27
NI	22	+	–	37
NI	16	+	+	37

Conclusion. Among selected women with early-stage cervical cancer, especially those with a tumor diameter of <20 mm, abdominal radical trachelectomy and pelvic lymphadenectomy is a fertility-sparing treatment option, even though the cumulative conception rate was not particularly high compared with that for women who had undergone a vaginal radical trachelectomy.

Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer

J-H Kim, J-Y Park, D-Y Kim, Y-M Kim, Y-T Kim, J-H Nam

Department of Obstetrics and Gynaecology, University of Ulsan College of Medicine, Asan Medical Centre, Seoul, Korea

Correspondence: Dr J-H Nam, Obstetrics and Gynaecology, College of Medicine, University of Ulsan, Asan Medical Centre, #388-1 Poongnap-2 dong, Songpa-gu, Seoul, 138-736, Korea. Email jhnam@amc.seoul.kr

Accepted 7 October 2009. Published Online 10 December 2009.

Characteristics	Variables
Age, mean (range), years	29 (22–37)
BMI, mean (range), kg/cm ²	20.8 (17.5–24.6)
Parity, n (%)	
0	20 (74.1)
1	5 (18.5)
2	2 (7.4)
Preoperative LEEP, n (%)	
No	12 (44.4)
Yes	15 (55.6)
FIGO stage, n (%)	
IB1	26 (96.3)
IIA	1 (3.7)
Tumour size, mean (range), cm	1.7 (0.4–3.5)
<2 cm, n (%)	19 (70.4)
≥2 cm, n (%)	8 (29.6)
Histology, n (%)	
Squamous cell carcinoma	20 (74.1)
Adenocarcinoma	6 (22.2)
Adenosquamous carcinoma	1 (3.7)
Histologic grade of tumour, n (%)	
Well differentiated	5 (18.5)
Moderately differentiated	14 (51.9)
Poorly differentiated	8 (29.6)
Number of LNs retrieved	
Para-aortic LNs, mean (range), n	4.3 (1–8)
Pelvic LNs, mean (range), n	24.6 (8–50)
Total LNs, mean (range), n	25.7 (8–50)

5 patients : LRT -> LRH conversion
27 patients : LRT

Recur – 1 patients,

Death – 6 patients

Successful pregnancy – 3 patients



ELSEVIER


THE JOURNAL OF
MINIMALLY INVASIVE
GYNECOLOGY

Original Article

Laparoscopic Nerve-Sparing Radical Trachelectomy: Surgical Technique and Outcome

Angel Martin, MD*, and Anna Torrent, MD

From the Department of Gynecology, Hospital Son Llàtzer, Balear Health Institute, Palma de Mallorca, Spain (both authors).



In conclusion, our preliminary experience shows that the laparoscopic approach may be a useful alternative to be considered in fertility-preserving surgery to treat cervical cancer for most centers that do not specialize in radical vaginal surgery. Therefore, this may favor diffusion of this surgical indication, which is increasingly demanded. However, larger clinical series with longer follow-up are needed to provide consistent data on the oncologic and reproductive outcomes of this procedure.

Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer

Pedro T. Ramirez ^{a,*}, Kathleen M. Schmeler ^a, Anais Malpica ^b, Pamela T. Soliman ^a

^a Department of Gynecologic Oncology, Unit 440, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

^b Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Published reports of robotic radical trachelectomy.

	Geisler et al. [8]	Persson et al. [9] ^a	Chuang et al. [10]	Our series (Ramirez et al.)
Number of patients	1	2	1	4
Operating time (min)	172	373 ^b	345	282 ^b
Estimated blood loss (ml)	100	125	200	62
Residual disease in trachelectomy specimen	No	No	No	No
Node count	26	26.5	43	20
Length of hospital stay (days)	N/A	3.5	2	1.5
Complications	None	Edema ^b	None	Neuropathy ^c

We have demonstrated that robotic radical trachelectomy is a safe and feasible procedure. Robotic surgery offers a minimally invasive approach to patients with early-stage cervical cancer who may be candidates for fertility-sparing surgery, and therefore this option should be discussed when we counsel our patients.

Fertility sparing surgery of Early cervical cancer

- Radical vaginal trachelectomy (RVT)
- Radical abdominal trachelectomy (RAT)
(laparoscopic, Robotic)
- Simple trachelectomy
- Conization with or without NACT

Backgrounds

- Post-trachelectomy biopsy after a diagnostic cone
 - no residual tumor (65%)

Plante M, Renaud MC, Francois H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. *Gynecol Oncol* 2004;94:614-23.

- Tumor size \leq 2cm, Pelvic LN (-), invasion \leq 10mm
 - parametrium invasion (0.6%)

Covens A, Rosen B, Murphy J, Laframboise S, Depetrillo AD, Lickrish G, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? *Gynecol Oncol* 2002;84:145-9.

- conization or simple trachelectomy
 - an alternative surgery for early stage low volume disease
 - need to adopt strict selection criteria to avoid recurrences and deaths in this group of highly curable patients.

NACT

- Neoadjuvant chemotherapy (NACT) can reduce the tumor size prior to fertility-sparing surgery.

Maneo A, Chiara S, Bonazzi C, Mangioni C. Neoadjuvant chemotherapy and conservative surgery for stage Ib1 cervical cancer. *Gynecol Oncol* 2008;111:438-43.

- 21 IB₁ patients received conization with PLND after NACT
- Using Cisplatin, paclitaxel and ifosfamide – 3 cycle
 - 5 patients – no residual lesion
 - After median follow up (69 months) – no recur
 - 10 pregnancies occurred in 6 patients.
(9 live births, 2 preterm deliveries and 1 first-trimester miscarriage)

Plante M, Lau S, Brydon L, Swenerton K, Leblanc R, Roy M. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage Ib1 cervical cancer: case report. *Gynecol Oncol* 2006;101:367-70.

- But alkylating agents such as ifosfamide and cisplatin can be detrimental to ovarian follicles, thus less gonadotoxic regimens should be evaluated in the future.

KGOG 1016



Wide conization following neoadjuvant chemotherapy in early stage cervical cancer patients with negative pelvic lymph node metastasis who eagerly want to conceive

Inclusion criteria


- Stage IB1 (tumor size < 2 cm) or IA2 with positive surgical margin (squamous, adenocarcinoma, adenosquamous)
- Baseline study includes USG, CT, MRI, or PET-CT to measure tumor size and tumor-localized to cervix
- No evidence of pelvic lymphadenopathy via laparoscopy or -tomy

Neoadjuvant chemoRx and Wide conization

- Paclitaxel 175mg/m² + carboplatin AUC 5 every 21 days, 3 cycles
 - Wide conization of uterine cervix with safe margin
-
- ❖ Primary endpoint: 5-yr disease-free survival ?
 - ❖ Required sample size: 110 pts

Treatment Algorithm for stage I cervical cancer

Stage I cervical cancer



Stage I cervical cancer
Want fertility preservation


IA,
IB1

Simple trachelectomy
or conization wth or
without NACT

Radical trachelectomy



KSGOC Practice Guideline for Cervical Cancer (I)



[‡] Tumor markers; SCC Ag, CEA, CA-125 if clinically indicated

[‡] Lab. studies; CBC with platelets, chemistry profile, IVP, ECG and urine analysis

[‡] Imaging studies; Chest X-ray, Abdomino-pelvic CT, MRI, PET if clinically indicated

* Intermediate-risk Factors

; Larger tumor size, Cervical Stromal Invasion to the middle or deep one third, Lymph-vascular space invasion

** High Risk factors ; Positive margin, Positive Lymph Nodes, Microscopic parametrial Involvement

• RT: radiation therapy • TH: total hysterectomy

• (M)RH: (modified) radical hysterectomy

• CCRT: concurrent chemoradiation

• VBT: Vaginal Brachytherapy

CLINICAL STAGE

PRIMARY TREATMENT

Stage IA1	→	Extrafascial hysterectomy or Observe if patient desires fertility or if inoperable (only if cone biopsy has negative margins) or Modified radical hysterectomy + pelvic lymph node dissection if lymphovascular invasion (category 2B)
Stage IA2	→	Radical hysterectomy + pelvic lymph node dissection ± para-aortic lymph node sampling or Brachytherapy + pelvic RT (point A dose: 75-80 Gy) ^b or <u>Radical trachelectomy for fertility preservation</u> + pelvic lymph node dissection ± para-aortic lymph node sampling
Stage IB1 and stage IIA (≤ 4 cm)	→	Radical hysterectomy + pelvic lymph node dissection ± para-aortic lymph node sampling (category 1) or Pelvic RT + brachytherapy (point A dose: 80-85 Gy) ^b or <u>Radical trachelectomy for fertility preservation for lesions (Stage IB1)</u> + pelvic lymph node dissection ± para-aortic lymph node sampling
Stage IB2 and stage IIA (> 4 cm) (also see CERV-4)	→	Radical hysterectomy + pelvic lymph node dissection + para-aortic lymph node sampling (category 2B) or Pelvic RT + concurrent cisplatin-containing chemotherapy ^c + brachytherapy (point A dose ≥ 85 Gy) ^b (category 1) or

In conclusion

- **Less radical surgery** should be confirmed in the future prospective randomized clinical trials in pts with **low risk early cervical cancer** so far.
- **Fertility-sparing radical trachelectomies** including both RVT and RAT are **a safe and feasible alternatives to RH** for early cervical cancer patients who desires to preserve fertility, with low morbidity, recurrence, and mortality rates, if performed under adequate selection criteria.
- **Simple trachelectomy or conization** for fertility sparing also **warrants further investigation**, which can be combined with NACT, as previously described. This will obviously require strict selection criteria to avoid recurrences and deaths in highly curable patients.

Thank you

